Dimethyltryptamine molecule (found in ayahuasca):

Image from PubChem

Ayahuasca Clinical Trials

Antidepressant Effects of Ayahuasca: a Randomized Placebo Controlled Trial in Treatment Resistant Depression

To see complete record on clinicaltrials.gov, please visit this link

Id: NCT02914769

Organisation Name: Universidade Federal do Rio Grande do Norte

Overal Status: Completed

Start Date: February 2014

Last Update: February 17, 2017

Lead Sponsor: Universidade Federal do Rio Grande do Norte

Brief Summary: The purpose of the present trial is to test the efficacy of Ayahuasca in treatment-resistant depression. Ayahuasca is a decoction of two plants, long used by Amazonian Amerindians. Traditionally, it is prepared by decoction of a bush (Psychotria viridis) with a liana (Banisteriopsis caapi). P. viridis is a rich source of N,N-dimethyltryptamine (DMT), a serotonergic agonist, and B. caapi contains potent monoamine oxidase-A inhibitors (MAOi-A), such as harmine, harmaline. The study is designed as a randomized placebo controlled trial with two parallel arms, and it will also evaluate changes of different biomarkers of depression including anatomical and functional Magnetic Resonance Imaging (MRI), serum levels of BDNF, TNF-a, cortisol, IL-6, and IL-10, polysomnography, neuropsychological, psychiatric scales and questionnaires.

  • Major Depression

Total execution time in seconds: 0.20575594902039